| Home | << 1 2 3 4 5 6 7 >> |
|
| Records | |||||
|---|---|---|---|---|---|
| Author | Turner, K.K.; Nielsen, B.D.; O'Connor, C.I.; Burton, J.L. | ||||
| Title | Bee pollen product supplementation to horses in training seems to improve feed intake: A pilot study | Type | Journal Article | ||
Year  |
2006 | Publication | Journal of Animal Physiology and Animal Nutrition | Abbreviated Journal | J Anim Physiol Anim Nutr (Berl) |
| Volume | 90 | Issue | 9-10 | Pages | 414-420 |
| Keywords | *Animal Nutrition Physiology; Animals; Antibody Formation; Bees; Detergents; Dietary Fiber/metabolism; Dietary Supplements; *Digestion; Eating/*drug effects; Exercise Test/veterinary; Female; Heart Rate/drug effects/physiology; Horses/blood/immunology/*physiology; Leukocyte Count/*veterinary; Male; Oxygen Consumption/drug effects/physiology; Physical Conditioning, Animal/*physiology; Pilot Projects; *Pollen; Random Allocation | ||||
| Abstract | The objective of this study was to determine the efficacy of supplementation of Dynamic Trio 50/50, a bee pollen-based product, to improve physical fitness, blood leukocyte profiles, and nutritional variables in exercised horses. Ten Arabian horses underwent a standardised exercise test (SET), then were pair-matched by sex and fitness and randomly assigned to BP (receiving 118 g of Dynamic Trio 50/50 daily) or CO (receiving 73 g of a placebo) for a period of 42 days. A total collection was conducted from days 18 to 21 on six geldings to determine nutrient retention and neutral detergent fibre (NDF) and acid detergent fibre (ADF) digestibility. Horses were exercise conditioned and completed another SET on day 42. V160 and V200 were calculated from SET heart rates (HR). Lactate, glucose, haematocrit (HT) and haemoglobin (HB) concentrations were determined from SET blood samples. Total leukocyte count, and circulating numbers of various leukocytes and IgG, IgM and IgA concentrations were determined in rest and recovery blood samples from both SETs. Geldings on BP (n = 3) ate more feed than CO. BP had less phosphorus excretion, and tended to retain more nitrogen. BP tended to digest more NDF and ADF while having lower NDF digestibility and tending to have lower ADF digestibility. No treatment differences existed for V160 and V200, HR, lactate, HT and HB. There was a trend for lymphocyte counts to be lower in BP than CO on day 42. Dynamic Trio 50/50 supplementation may have a positive effect on performance by helping horses in training meet their potentially increased nutrient demands by increasing feed intake and thus nutrient retention. | ||||
| Address | Department of Animal Science, Michigan State University, East Lansing, MI 48824, USA. kturner@uga.edu | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0931-2439 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:16958799 | Approved | no | ||
| Call Number | Equine Behaviour @ team @ | Serial | 4237 | ||
| Permanent link to this record | |||||
| Author | Hodgson, D.; Howe, S.; Jeffcott, L.; Reid, S.; Mellor, D.; Higgins, A. | ||||
| Title | Effect of prolonged use of altrenogest on behaviour in mares | Type | |||
| Year |
2005 | Publication | Veterinary journal (London, England : 1997) | Abbreviated Journal | Vet J |
| Volume | 169 | Issue | 1 | Pages | 113-115 |
| Keywords | Administration, Oral; Anabolic Agents/adverse effects/*pharmacology; Animals; Behavior, Animal/*drug effects; Body Constitution/drug effects; Body Weight/drug effects; *Doping in Sports; Female; Horses/*physiology; Social Behavior; Social Dominance; Time Factors; Trenbolone/adverse effects/*analogs & derivatives/*pharmacology | ||||
| Abstract | Erratum in: Vet J. 2005 May;169(3):321. Corrected and republished in: Vet J. 2005 May;169(3):322-5. Oral administration of altrenogest for oestrus suppression in competition horses is believed to be widespread in some equestrian disciplines, and can be administered continuously for several months during a competition season. To examine whether altrenogest has any anabolic or other potential performance enhancing properties that may give a horse an unfair advantage, we examined the effect of oral altrenogest (0.044 mg/kg), given daily for a period of eight weeks, on social hierarchy, activity budget, body-mass and body condition score of 12 sedentary mares. We concluded that prolonged oral administration of altrenogest at recommended dose rates to sedentary mares resulted in no effect on dominance hierarchies, body mass or condition score. |
||||
| Address | Faculty of Veterinary Science, University of Sydney, Private Mailbag 4, Narellan Delivery Centre, Narellan, NSW 2567, Australia. davidh@camden.usyd.edu.au | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 1090-0233 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15683772 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 671 | ||
| Permanent link to this record | |||||
| Author | Nicol, C.J.; Adachi, M.; Akiyama, T.E.; Gonzalez, F.J. | ||||
| Title | PPARgamma in endothelial cells influences high fat diet-induced hypertension | Type | Journal Article | ||
| Year |
2005 | Publication | American journal of hypertension : journal of the American Society of Hypertension | Abbreviated Journal | Am J Hypertens |
| Volume | 18 | Issue | 4 Pt 1 | Pages | 549-556 |
| Keywords | Administration, Oral; Animals; Antihypertensive Agents/pharmacology; Blood Pressure/drug effects; Diabetes Mellitus, Type 2/physiopathology; Dietary Fats/*administration & dosage/pharmacology; Dose-Response Relationship, Drug; Endothelial Cells/*metabolism; Female; Heart Rate/drug effects; Hypertension/*etiology; Ligands; Male; Mice; Mice, Knockout; PPAR gamma/*metabolism; Sodium Chloride/administration & dosage/pharmacology; Thiazolidinediones/pharmacology | ||||
| Abstract | BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands improve human hypertension. However, the mechanism and site of this effect remains unknown, confounded by PPARgamma expression in many cell types, including endothelial cells (ECs). METHODS: To evaluate the vascular role of PPARgamma we used a conditional null mouse model. Specific disruption of PPARgamma in ECs was created by crossing Tie2-Cre+ transgenic (T2T+) and PPARgamma-floxed (fl/fl) mice to generate PPARgamma (fl/fl)T2T+ (PPARgamma E-null) mice. Conscious 8- to 12-week-old congenic PPARgamma (fl/fl)Cre- (wild type) and PPARgamma E-null mice were examined for changes in systolic blood pressure (BP) and heart rate (HR), untreated, after 2 months of salt-loading (drinking water), and after treatment for 3 months with high fat (HF) diet alone or supplemented during the last 2 weeks with rosiglitazone (3 mg/kg/d). RESULTS: Untreated PPARgamma E-nulls were phenotypically indistinguishable from wild-type littermates. However, compared to similarly treated wild types, HF-treated PPARgamma E-nulls had significantly elevated systolic BP not seen after normal diet or salt-loading. Despite sex-dependent baseline differences, salt-loaded and HF-treated PPARgamma E-nulls of either sex had significantly elevated HR versus wild types. Interestingly, rosiglitazone improved serum insulin levels, but not HF diet-induced hypertension, in PPARgamma E-null mice. CONCLUSIONS: These results suggest that PPARgamma in ECs not only is an important regulator of hypertension and HR under stressed conditions mimicking those arising in type 2 diabetics, but also mediates the antihypertensive effects of rosiglitazone. These data add evidence supporting a beneficial role for PPARgamma-specific ligands in the treatment of hypertension, and suggest therapeutic strategies targeting ECs may prove useful. | ||||
| Address | Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0895-7061 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15831367 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 69 | ||
| Permanent link to this record | |||||
| Author | Crosby, M.B.; Svenson, J.L.; Zhang, J.; Nicol, C.J.; Gonzalez, F.J.; Gilkeson, G.S. | ||||
| Title | Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide | Type | Journal Article | ||
| Year |
2005 | Publication | The Journal of pharmacology and experimental therapeutics | Abbreviated Journal | J Pharmacol Exp Ther |
| Volume | 312 | Issue | 1 | Pages | 69-76 |
| Keywords | Animals; Cell Line; Gene Expression/drug effects; Macrophages/drug effects/metabolism; Mice; Mice, Inbred C57BL; Nitric Oxide/*metabolism; Nitric Oxide Synthase/*metabolism; Nitric Oxide Synthase Type II; PPAR delta/metabolism; PPAR gamma/*agonists/deficiency; Thiazolidinediones/pharmacology | ||||
| Abstract | Peroxisome proliferation-activated receptor (PPAR)gamma agonists inhibit inducible nitric-oxide synthase (iNOS), tumor necrosis factor-alpha, and interleukin-6. Because of these effects, synthetic PPARgamma agonists, including thiazolidinediones, are being studied for their impact on inflammatory disease. The anti-inflammatory concentrations of synthetic PPARgamma agonists range from 10 to 50 microM, whereas their binding affinity for PPARgamma is in the nanomolar range. The specificity of synthetic PPARgamma agonists for PPARgamma at the concentrations necessary for anti-inflammatory effects is thus in question. We report that PPARgamma is not necessary for the inhibition of iNOS by synthetic PPARgamma agonists. RAW 264.7 macrophages possess little PPARgamma, yet lipopolysaccharide (LPS)/interferon (IFN)gamma-induced iNOS was inhibited by synthetic PPARgamma agonists at 20 microM. Endogenous PPARgamma was inhibited by the transfection of a dominant-negative PPARgamma construct into murine mesangial cells. In the transfected cells, synthetic PPARgamma agonists inhibited iNOS production at 10 microM, similar to nontransfected cells. Using cells from PPARgamma Cre/lox conditional knockout mice, baseline and LPS/IFNgamma-induced nitric oxide levels were higher in macrophages lacking PPARgamma versus controls. However, synthetic PPARgamma agonists inhibited iNOS at 10 microM in the PPARgamma-deficient cells, similar to macrophages from wild-type mice. These results indicate that PPARgamma is not necessary for inhibition of iNOS expression by synthetic PPARgamma agonists at concentrations over 10 microM. Intrinsic PPARgamma function, in the absence of synthetic agonists, however, may play a role in inflammatory modulation. | ||||
| Address | Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0022-3565 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15356214 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 73 | ||
| Permanent link to this record | |||||
| Author | Lyda, R.O.; Hall, J.R.; Kirkpatrick, J.F. | ||||
| Title | A comparison of Freund's Complete and Freund's Modified Adjuvants used with a contraceptive vaccine in wild horses (Equus caballus) | Type | Journal Article | ||
| Year |
2005 | Publication | Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians | Abbreviated Journal | J Zoo Wildl Med |
| Volume | 36 | Issue | 4 | Pages | 610-616 |
| Keywords | Animals; Antibody Formation; Contraception, Immunologic/*veterinary; Estrus/drug effects; Female; Freund's Adjuvant/administration & dosage/adverse effects/*immunology; Horses/immunology/*physiology; *Vaccines, Contraceptive; Zona Pellucida/*immunology | ||||
| Abstract | Fifteen captive wild mares (Equus caballus) were treated with porcine zona pellucida contraceptive vaccine and either Freund's Complete Adjuvant (n = 7) or Freund's Modified Adjuvant (n = 8). All mares received a booster inoculation of porcine zona pellucida plus Freund's Incomplete Adjuvant a month later. Anti-porcine zona pellucida antibodies were measured over 10 mo following the initial inoculation. There were no significant differences in antibody titers at any point during the 10 mo, and seven of the eight mares in the Freund's Modified Adjuvant group were above the 60% level at the end of the study, which is considered to be the contraceptive threshold for horses. There were no significant differences in titers between pregnant and nonpregnant horses, nor was there a significant correlation between age and titers. One local injection site reaction occurred after booster treatment with Freund's Incomplete Adjuvant, and 11 healthy foals were born during the course of the study. These data suggest that Freund's Modified Adjuvant is an acceptable substitute for Freund's Complete Adjuvant in certain free-ranging and captive wildlife species. | ||||
| Address | Science and Conservation Center, 2100 South Shiloh Road, Billings, Montana 59106, USA | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 1042-7260 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:17312717 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 139 | ||
| Permanent link to this record | |||||
| Author | Guo, G.L.; Moffit, J.S.; Nicol, C.J.; Ward, J.M.; Aleksunes, L.A.; Slitt, A.L.; Kliewer, S.A.; Manautou, J.E.; Gonzalez, F.J. | ||||
| Title | Enhanced acetaminophen toxicity by activation of the pregnane X receptor | Type | Journal Article | ||
| Year |
2004 | Publication | Toxicological sciences : an official journal of the Society of Toxicology | Abbreviated Journal | Toxicol Sci |
| Volume | 82 | Issue | 2 | Pages | 374-380 |
| Keywords | Acetaminophen/pharmacokinetics/*toxicity; Analgesics, Non-Narcotic/pharmacokinetics/*toxicity; Animals; Aryl Hydrocarbon Hydroxylases/biosynthesis; Biotransformation; Blotting, Northern; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Membrane Proteins; Mice; Mice, Knockout; Oxidoreductases, N-Demethylating/biosynthesis; Pregnenolone Carbonitrile/pharmacology; Receptors, Cytoplasmic and Nuclear/*drug effects; Receptors, Steroid/*drug effects; Sulfhydryl Compounds/metabolism | ||||
| Abstract | The pregnane X receptor (PXR) is a ligand-activated transcription factor and member of the nuclear receptor superfamily. Activation of PXR represents an important mechanism for the induction of cytochrome P450 3A (CYP3A) enzymes that can convert acetaminophen (APAP) to its toxic intermediate metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Therefore, it was hypothesized that activation of PXR plays a major role in APAP-induced hepatotoxicity. Pretreatment with the PXR activator, pregnenolone 16alpha-carbonitrile (PCN), markedly enhanced APAP-induced hepatic injury, as revealed by increased serum ALT levels and hepatic centrilobular necrosis, in wild-type but not in PXR-null mice. Further analysis showed that following PCN treatment, PXR-null mice had lower CYP3A11 expression, decreased NAPQI formation, and increased maintenance of hepatic glutathione content compared to wild-type mice. Thus, these results suggest that PXR plays a critical role in APAP-induced hepatic toxicity, probably by inducing CYP3A11 expression and hence increasing bioactivation. | ||||
| Address | Laboratory of Metabolism, CCR, NCI, NIH, Bethesda, Maryland 20892, USA | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 1096-6080 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15456926 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 71 | ||
| Permanent link to this record | |||||
| Author | Jeong, S.; Han, M.; Lee, H.; Kim, M.; Kim, J.; Nicol, C.J.; Kim, B.H.; Choi, J.H.; Nam, K.-H.; Oh, G.T.; Yoon, M. | ||||
| Title | Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice | Type | Journal Article | ||
| Year |
2004 | Publication | Metabolism: clinical and experimental | Abbreviated Journal | Metabolism |
| Volume | 53 | Issue | 10 | Pages | 1284-1289 |
| Keywords | Adipose Tissue/*anatomy & histology/drug effects; Animals; Antilipemic Agents/*pharmacology; Body Composition/*drug effects; Body Weight/drug effects; Dietary Fats/*pharmacology; Eating/drug effects; Fatty Acids/metabolism; Female; Gene Expression Regulation/drug effects; Leptin/metabolism; Liver/metabolism; Mice; Mice, Inbred C57BL; Ovariectomy; Procetofen/*pharmacology; RNA, Messenger/biosynthesis/genetics; Receptors, Cytoplasmic and Nuclear/biosynthesis/genetics/metabolism; Transcription Factors/biosynthesis/genetics/metabolism; Weight Gain/*drug effects | ||||
| Abstract | Our previous study suggested that fenofibrate affects obesity and lipid metabolism in a sexually dimorphic manner in part through the differential activation of hepatic peroxisome proliferator-activated receptor alpha (PPARalpha) in male and female C57BL/6J mice. To determine whether fenofibrate reduces body weight gain and adiposity in female sham-operated (Sham) and ovariectomized (OVX) C57BL/6J mice, the effects of fenofibrate on not only body weight, white adipose tissue (WAT) mass, and food intake, but also the expression of both leptin and PPARalpha target genes were measured. Compared to their respective low-fat diet-fed controls, both Sham and OVX mice exhibited increases in body weight and WAT mass when fed a high-fat diet. Fenofibrate treatment decreased body weight gain and WAT mass in OVX, but not in Sham mice. Furthermore, fenofibrate increased the mRNA levels of PPARalpha target genes encoding peroxisomal enzymes involved in fatty acid beta-oxidation, and reduced apolipoprotein C-III (apo C-III) mRNA, all of which were expressed at higher levels in OVX compared to Sham mice. However, leptin mRNA levels were found to positively correlate with WAT mass, and food intake was not changed in either OVX or Sham mice following fenofibrate treatment. These results suggest that fenofibrate differentially regulates body weight and adiposity due in part to differences in PPARalpha activation, but not to differences in leptin production, between female OVX and Sham mice. | ||||
| Address | Department of Life Sciences, Mokwon University, Taejon, Korea | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0026-0495 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15375783 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 72 | ||
| Permanent link to this record | |||||
| Author | Cheung, C.; Akiyama, T.E.; Ward, J.M.; Nicol, C.J.; Feigenbaum, L.; Vinson, C.; Gonzalez, F.J. | ||||
| Title | Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha | Type | Journal Article | ||
| Year |
2004 | Publication | Cancer research | Abbreviated Journal | Cancer Res |
| Volume | 64 | Issue | 11 | Pages | 3849-3854 |
| Keywords | Animals; Anticholesteremic Agents/pharmacology; Carcinogens/pharmacology; Cell Division; DNA Replication/drug effects; Fatty Acids/metabolism; Hepatocytes/cytology/drug effects/metabolism/*physiology; Humans; Mice; Mice, Transgenic; Oxidation-Reduction; Peroxisome Proliferators/pharmacology; Pyrimidines/pharmacology; Receptors, Cytoplasmic and Nuclear/genetics/*physiology; Species Specificity; Transcription Factors/genetics/*physiology | ||||
| Abstract | Lipid-lowering fibrate drugs function as agonists for the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Sustained activation of PPARalpha leads to the development of liver tumors in rats and mice. However, humans appear to be resistant to the induction of peroxisome proliferation and the development of liver cancer by fibrate drugs. The molecular basis of this species difference is not known. To examine the mechanism determining species differences in peroxisome proliferator response between mice and humans, a PPARalpha-humanized mouse line was generated in which the human PPARalpha was expressed in liver under control of the tetracycline responsive regulatory system. The PPARalpha-humanized and wild-type mice responded to treatment with the potent PPARalpha ligand Wy-14643 as revealed by induction of genes encoding peroxisomal and mitochondrial fatty acid metabolizing enzymes and resultant decrease of serum triglycerides. However, surprisingly, only the wild-type mice and not the PPARalpha-humanized mice exhibited hepatocellular proliferation as revealed by elevation of cell cycle control genes, increased incorporation of 5-bromo-2'-deoxyuridine into hepatocyte nuclei, and hepatomegaly. These studies establish that following ligand activation, the PPARalpha-mediated pathways controlling lipid metabolism are independent from those controlling the cell proliferation pathways. These findings also suggest that structural differences between human and mouse PPARalpha are responsible for the differential susceptibility to the development of hepatocarcinomas observed after treatment with fibrates. The PPARalpha-humanized mice should serve as models for use in drug development and human risk assessment and to determine the mechanism of hepatocarcinogenesis of peroxisome proliferators. | ||||
| Address | Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0008-5472 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15172993 | Approved | no | ||
| Call Number | refbase @ user @ | Serial | 74 | ||
| Permanent link to this record | |||||
| Author | Rietmann, T.R.; Stauffacher, M.; Bernasconi, P.; Auer, J.A.; Weishaupt, M.A. | ||||
| Title | The association between heart rate, heart rate variability, endocrine and behavioural pain measures in horses suffering from laminitis | Type | Journal Article | ||
| Year |
2004 | Publication | Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine | Abbreviated Journal | J Vet Med A Physiol Pathol Clin Med |
| Volume | 51 | Issue | 5 | Pages | 218-225 |
| Keywords | Animals; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Autonomic Nervous System; Behavior, Animal; Electrophysiology/*methods; Endocrine System; Female; Heart Rate; Horse Diseases/blood/drug therapy/*physiopathology; Horses; Joint Diseases/physiopathology/*veterinary; Male; Pain/physiopathology/*veterinary; Pain Measurement/*veterinary; Predictive Value of Tests | ||||
| Abstract | The objective of this study was to compare the stress response of horses suffering from laminitis after short- and long-term treatment with the intent to evaluate power spectral analysis of heart rate variability (HRV) for pain monitoring. Data were collected from 19 horses with acute or chronic exacerbating laminitis without known primary disease before and after treatment with non-steroidal anti-inflammatory drugs (NSAID). Recordings were carried out the day after admission to the equine hospital. Measurements were repeated on day 7 of the treatment. The recorded parameters included a clinical orthopaedic index (OLPI: Obel-grade plus hoof tester score), frequency of weight-shifting between contralateral limbs, mean beat-to-beat interval (R-R) duration, standard deviation of continuous R-R intervals, low- (LF) and high-frequency (HF) components of HRV, sympatho-vagal balance (LF/HF), and plasma concentration of cortisol, adrenalin and noradrenalin. The LF represents mainly sympathetic influences on the heart whereas HF is mediated by the parasympathetic tone. Weight-shifting and OLPI decreased significantly with treatment. The LF normalized units (n.u.) decreased after NSAID from 60.41 +/- 21.42 to 51.12 +/- 19.81 and was 49.33 +/- 22.64 on day 7, whereas HF n.u. increased from 35.07 +/- 20.02 to 43.14 +/- 18.30 and was 45.98 +/- 23.00 on day 7. Hormone levels showed no tendency to change with treatment. The OLPI was only correlated with LF/HF, LF and HF (R = 0.57, 0.55 and -0.54 respectively). Significant negative correlations existed between HFn.u. and weight-shifting frequency (R = -0.37), HFn.u. and adrenalin (R = -0.47), and HFn.u. and noradrenalin (R = 0.33). The LFn.u. only correlated positively with adrenalin. Cortisol levels were poorly associated with the other parameters. Determination of the sympatho-vagal influences on cardiac function may offer complementary information for reliable assessment of pain and may represent a valuable alternative method to catecholamine measurements. | ||||
| Address | Equine Hospital, Faculty of Veterinary Medicine, University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 0931-184X | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15315700 | Approved | no | ||
| Call Number | Serial | 1899 | |||
| Permanent link to this record | |||||
| Author | Yamazaki, Y.; Shinohara, N.; Watanabe, S. | ||||
| Title | Visual discrimination of normal and drug induced behavior in quails (Coturnix coturnix japonica) | Type | Journal Article | ||
| Year |
2004 | Publication | Animal Cognition | Abbreviated Journal | Anim. Cogn. |
| Volume | 7 | Issue | 2 | Pages | 128-132 |
| Keywords | Animals; Behavior, Animal/*drug effects; Classification; Coturnix/*physiology; *Discrimination Learning; *Generalization (Psychology); Ketamine/pharmacology; Male; Methamphetamine/pharmacology; *Pattern Recognition, Visual; Video Recording; Visual Perception | ||||
| Abstract | The ability to discriminate the physical states of others could be an adaptive behavior, especially for social animals. For example, the ability to discriminate illness behavior would be helpful for avoiding spoiled foods. We report on an experiment with Japanese quails testing whether these birds can discriminate the physical states of conspecifics. The quails were trained to discriminate between moving video images of quails injected with psychoactive drugs and those in a normal (not injected) condition. Methamphetamine (stimulant) or ketamine (anesthetic) were used to produce drug-induced behaviors in conspecifics. The former induced hyperactive behavior and the latter hypoactive behavior. The subject quails could learn the discrimination and showed generalization to novel images of the drug-induced behaviors. They did not, however, show discriminative behavior according to the type and dosage of the drugs. Thus, they categorized the behavior not on the basis of degree of activity, but on the basis of abnormality. | ||||
| Address | Biopsychologie, Institut fur Kognitive Neurowissenschaft, Fakultat fur Psychologie, Ruhr-Universitat Bochum, 44780 Bochum, Germany. yumyam@bio.psy.ruhr-uni-bochum.de | ||||
| Corporate Author | Thesis | ||||
| Publisher | Place of Publication | Editor | |||
| Language | English | Summary Language | Original Title | ||
| Series Editor | Series Title | Abbreviated Series Title | |||
| Series Volume | Series Issue | Edition | |||
| ISSN | 1435-9448 | ISBN | Medium | ||
| Area | Expedition | Conference | |||
| Notes | PMID:15069613 | Approved | no | ||
| Call Number | Equine Behaviour @ team @ | Serial | 2527 | ||
| Permanent link to this record | |||||